title: Rescue administration of a helper-dependent adenovirus vector with long-term efficacy in dogs with glycogen storage disease type Ia.
abstract: Glycogen storage disease type Ia (GSD-Ia) stems from glucose-6-phosphatase (G6Pase) deficiency and causes hypoglycemia, hepatomegaly, hypercholesterolemia and lactic acidemia. Three dogs with GSD-Ia were initially treated with a helper-dependent adenovirus encoding a human G6Pase transgene (HDAd-cG6Pase serotype 5) on postnatal day 3. Unlike untreated dogs with GSD-Ia, all three dogs initially maintained normal blood glucose levels. After 6-22 months, vector-treated dogs developed hypoglycemia, anorexia and lethargy, suggesting that the HDAd-cG6Pase serotype 5 vector had lost efficacy. Liver biopsies collected at this time revealed significantly elevated hepatic G6Pase activity and reduced glycogen content, when compared with affected dogs treated only by frequent feeding. Subsequently, the HDAd-cG6Pase serotype 2 vector was administered to two dogs, and hypoglycemia was reversed; however, renal dysfunction and recurrent hypoglycemia complicated their management. Administration of a serotype 2 HDAd vector prolonged survival in one GSD-Ia dog to 12 months of age and 36 months of age in the other, but the persistence of long-term complications limited HDAd vectors in the canine model for GSD-Ia.
authors.affiliation: College of Veterinary Medicine, North Carolina State University, Raleigh, NC, USA.
authors.forename: B
authors.initials: B
authors.lastname: Crane
authors.forename: X
authors.initials: X
authors.lastname: Luo
authors.forename: A
authors.initials: A
authors.lastname: Demaster
authors.forename: K D
authors.initials: KD
authors.lastname: Williams
authors.forename: D M
authors.initials: DM
authors.lastname: Kozink
authors.forename: P
authors.initials: P
authors.lastname: Zhang
authors.forename: T T
authors.initials: TT
authors.lastname: Brown
authors.forename: C R
authors.initials: CR
authors.lastname: Pinto
authors.forename: K
authors.initials: K
authors.lastname: Oka
authors.forename: F
authors.initials: F
authors.lastname: Sun
authors.forename: M W
authors.initials: MW
authors.lastname: Jackson
authors.forename: L
authors.initials: L
authors.lastname: Chan
authors.forename: D D
authors.initials: DD
authors.lastname: Koeberl
mesh_terms: D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D001835:Body Weight; D004283:Dog Diseases / Q000628:therapy*; D004285:Dogs; D015316:Genetic Therapy / Q000009:adverse effects / Q000379:methods*; D005822:Genetic Vectors; D005952:Glucose-6-Phosphatase / Q000235:genetics*; D005953:Glycogen Storage Disease Type I / Q000628:therapy* / Q000662:veterinary; D007003:Hypoglycemia / Q000150:complications / Q000517:prevention & control
chemical_list: D005952:Glucose-6-Phosphatase